Vol. 1 No. 8 (2021)
Reimbursement Reviews

Luspatercept (Reblozyl)

Published August 10, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses luspatercept (Reblozyl), 25 mg/vial, 75 mg/vial, powder for solution for subcutaneous injection.
  • Indication: For the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.